<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02179866</url>
  </required_header>
  <id_info>
    <org_study_id>BP29279</org_study_id>
    <secondary_id>2014-000277-40</secondary_id>
    <nct_id>NCT02179866</nct_id>
  </id_info>
  <brief_title>A Single-center Study to Investigate How Quickly and to What Extent a Radioactive Dose of RO5285119 is Absorbed, Metabolized and Eliminated From the Body of Healthy Male Volunteers</brief_title>
  <official_title>SINGLE-CENTER, OPEN-LABEL, NON-RANDOMIZED STUDY INVESTIGATING THE EXCRETION BALANCE, PHARMACOKINETICS AND METABOLISM OF A SINGLE ORAL DOSE OF [14C]-LABELED RO5285119 IN HEALTHY MALE SUBJECTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This study is designed to investigate the absorption, distribution, metabolism and&#xD;
      elimination of a single oral dose of radiolabeled [14C]-labeled RO5285119 in healthy male&#xD;
      participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total recovery of radioactivity over time in urine and feces expressed as a percentage of the total radioactive dose administered</measure>
    <time_frame>Up to Day 17</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic profile of total drug-related material, RO5285119 and its metabolites, as appropriate in plasma, estimated Cmax</measure>
    <time_frame>Up to Day 17</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of dose recovered as total radioactivity, i.e. relative abundance of RO5285119 and its metabolite(s) in plasma, urine and feces</measure>
    <time_frame>Up to Day 17</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 28 days after the last dose of study drug</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>[14C]-labeled RO5285119</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose - drinking solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO5285119</intervention_name>
    <description>Single oral dose of RO5285119 with approximately 2.1 MBq (56.6 uCi) [14C]-radiolabeled RO5285119 administered as a drinking solution under fasted conditions on Day -1</description>
    <arm_group_label>[14C]-labeled RO5285119</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male participants, 35 to 64 years of age, inclusive&#xD;
&#xD;
          -  For men with a female partner of child-bearing potential: Agreement to use two methods&#xD;
             of contraception, including one barrier method e.g. condom, during the treatment&#xD;
             period and for at least 3 months after the last dose of study drug&#xD;
&#xD;
          -  Participants who do not intend to donate sperm until at least 3 months after the last&#xD;
             dose of the study drug&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of any clinically significant gastrointestinal, renal, hepatic,&#xD;
             broncho-pulmonary, neurological, psychiatric, cardiovascular, endocrinological,&#xD;
             hematological or allergic disease, metabolic disorder, cancer or cirrhosis&#xD;
&#xD;
          -  Any personal or familial history of seizures, epilepsy or other convulsive condition,&#xD;
             previous significant head trauma, or other factors predisposing to seizures&#xD;
&#xD;
          -  Any major illness within one month before the screening examination or any febrile&#xD;
             illness within one week prior to screening and up to first dose administration&#xD;
&#xD;
          -  Concomitant disease or condition that could interfere with, or treatment of which&#xD;
             might interfere with, the conduct of the study, or that would, in the opinion of the&#xD;
             investigator, pose an unacceptable risk to a subject&#xD;
&#xD;
          -  History or presence of any clinically relevant ECG abnormalities, cardiovascular or&#xD;
             cerebrovascular disease&#xD;
&#xD;
          -  History of myopathy or muscle disorder&#xD;
&#xD;
          -  History or evidence of any medical condition potentially altering the absorption,&#xD;
             metabolism or elimination of drugs&#xD;
&#xD;
          -  Any CYP3A inhibitor within 2 weeks or within 5 times the elimination half-life,&#xD;
             whichever is longer, prior to dosing&#xD;
&#xD;
          -  Any CYP3A inducer within 4 weeks or within 5 times the elimination half-life,&#xD;
             whichever is longer, prior to dosing&#xD;
&#xD;
          -  Infrequent bowel movements (less than once per 24 hours on average)&#xD;
&#xD;
          -  Regular work with ionizing radiation or radioactive material&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Zuidlaren</city>
        <zip>9471 GP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>June 11, 2014</study_first_submitted>
  <study_first_submitted_qc>June 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2014</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

